ACE up the sleeve – are vascular patients medically optimized?

References

• CriquiMHFronekABarrett-ConnorEKlauberMRGabrielSGoodmanDThe prevalence of peripheral arterial disease in a defined populationCirculation19857135105153156006
   PubMed Web of Science ®Google Scholar
• KannelWBMcGeeDLUpdate on some epidemiologic features of intermittent claudication: the Framingham StudyJ Am Geriatr Soc198533113183965550
   PubMed Web of Science ®Google Scholar
• CriquiMHLangerRDFronekAMortality over a period of 10 years in patients with peripheral arterial diseaseN Engl J Med199232663813861729621
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGJMurphyMBPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet200236093461623163012457784
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsAntiplatelet Trialists’ CollaborationBMJ19943086921811068298418
   PubMed Web of Science ®Google Scholar
• RiceTWLumsdenABOptimal medical management of peripheral arterial diseaseVasc Endovascular Surg200640431232716959725
   PubMedGoogle Scholar
• FeringaHHvan WaningVHBaxJJCardioprotective medication is associated with improved survival in patients with peripheral arterial diseaseJ Am Coll Cardiol20064761182118716545650
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222723915249516
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupMajor outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA2002288232998300712479764
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• KinlaySPotential vascular benefits of statinsAm J Med2005118Suppl 12A626716356810
   PubMedGoogle Scholar
• FaggiottoAPaolettiRState-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of actionHypertension1999344 Pt 298799610523396
   PubMed Web of Science ®Google Scholar
• FreemantleNClelandJYoungPMasonJHarrisonJBeta blockade after myocardial infarction: systematic review and meta regression analysisBMJ199931872001730173710381708
   PubMed Web of Science ®Google Scholar
• Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• ParavastuSCMendoncaDda SilvaABeta blockers for peripheral arterial diseaseCochrane Database Syst Rev20084CD00550818843692
   PubMedGoogle Scholar
• RadackKDeckCBeta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trialsArch Intern Med19911519176917761679624
   PubMedGoogle Scholar
• AronowWSAhnCEffect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial diseaseAm J Cardiol200187111284128611377356
   PubMed Web of Science ®Google Scholar
• AhimastosAALawlerAReidCMBlomberyPAKingwellBABrief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trialAnn Intern Med2006144566066416670135
   PubMedGoogle Scholar
• AhimastosAADartAMLawlerABlomberyPAKingwellBAReduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patientsJ Hypertens20082651037104218398348
   PubMed Web of Science ®Google Scholar
• ONTARGETInvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• ACE Inhibitors in Diabetic Nephropathy Trialist GroupShould all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient dataAnn Intern Med2001134537037911242497
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGBainRPRohdeRDThe effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study GroupN Engl J Med199332920145614628413456
   PubMed Web of Science ®Google Scholar
• HouFFZhangXZhangGHEfficacy and safety of benazepril for advanced chronic renal insufficiencyN Engl J Med2006354213114016407508
   PubMed Web of Science ®Google Scholar